速递｜多肽龙头翰宇药业高层换血，前恒瑞副总裁空降补位！

Group 1 - The core viewpoint of the article highlights the recent management restructuring at Hanyu Pharmaceutical, indicating a shift towards a dual CEO structure with both external and internal leadership to enhance operational efficiency [2][4][6] Group 2 - The management changes began in August 2025 with the resignation of the Vice President responsible for overseas marketing, followed by further adjustments in October and November, indicating a trend of personnel turnover across key operational areas [4][6] - The adjustments cover critical management aspects including market expansion, capital market communication, and overall company operations, suggesting a comprehensive overhaul of the management structure within a short timeframe [6]